Probi and Sinopharm enter strategic partnership in China

摘要

The Swedish probiotic supplier, Probi® and Sinopharm, one of China's largest pharmaceutical & healthcare companies enter a partnership to expand the offering of premium probiotic offerings in the Chinese market. Sinopharm will launch three probiotic supplements within the immune health, bone health and iron absorption areas based on Probi's scientifically proven probiotic strains.Zhang Jian Ge, Director Pharmaceutical & Chemical Division of Sinopharm, states: "Sinopharm continues to commit to our strong sense of social responsibility of "caring for life, attending to health". Guided by our core value "All for health, health for all", Sinopharm's recent strategic partnership with Probi, especially its best-in-class R&D capability helps us contribute with positive impact to China's consumer healthcare industry."